Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
“We are delighted with the robust sales growth in the third quarter, during which we have continued to increase commercial capacity and deliver CARVYKTI to more multiple myeloma patients around the world. The positive data from our CARTITUDE-4 study ...
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30,
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline results
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc.
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
(GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD),
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects
FierceBiotech7d
ASH: New Gilead-Arcellx data build CAR-T's case against Carvykti in advanced multiple myeloma
Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...
Cure Today7d
Carvykti Effective for R/R Multiple Myeloma in Real-World Setting
The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.
BioSpace6d
Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma
Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...
pharmaphorum4d
Trial sets up earlier use of J&J's Carvykti in myeloma
The study – which tested Carvykti in patients with one to three lines of prior therapy – gives J&J an opportunity to leapfrog Bristol-Myers Squibb and 2Seventy bio's rival BCMA CAR-T therapy ...
GlobalData on MSN1mon
Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial
Johnson & Johnson has reported data from the Phase III CARTITUDE-4 clinical trial where CARVYKTI (ciltacabtagene autoleucel ...
Legend Biotech’s CARVYKTI Shows Promising Myeloma Results
Legend Biotech (LEGN) has released an update. Legend Biotech’s CARVYKTI therapy, featured at the American Society of Hematology meeting, ...
Yahoo Finance8d
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI ®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...
BioSpace4h
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
Nasdaq7d
Genscript Biotech’s CARVYKTI Shows Promise in Myeloma Treatment
Their CARVYKTI therapy, which targets BCMA, has been approved by both the FDA and European Commission, and is expanding its reach globally. This development highlights potential growth ...
Cancer cell therapy from Arcellx, Gilead shows promise in early data
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other ...
Investing7d
Legend Biotech's SWOT analysis: carvykti success drives stock outlook
Legend Biotech Corp (NASDAQ:LEGN), a biopharmaceutical company specializing in novel cell therapies for oncology, has been making waves in the healthcare sector with its flagship product, Carvykti.